Literature DB >> 16041037

Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA.

Jennifer L Taylor1, Diane J Ordway, Jolynn Troudt, Mercedes Gonzalez-Juarrero, Randall J Basaraba, Ian M Orme.   

Abstract

Resistant C57BL/6 mice infected in the lungs with Mycobacterium tuberculosis and then therapeutically vaccinated with Mycobacterium leprae-derived hsp65 DNA develop severe granulomatous pneumonia and tissue damage. Analysis of cells accumulating in the lungs of these animals revealed substantial increases in T cells secreting tumor necrosis factor alpha and CD8 cells staining positive for granzyme B. Stimulation of lung cells ex vivo revealed very high levels of interleukin-10, some of which was produced by B-1 B cells. This was probably an anti-inflammatory response, since lung pathology was dramatically worsened in B-cell gene-disrupted mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041037      PMCID: PMC1201265          DOI: 10.1128/IAI.73.8.5189-5193.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

Authors:  A Weinrich Olsen; L A van Pinxteren; L Meng Okkels; P Birk Rasmussen; P Andersen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 2.  The pathogenesis of tuberculosis.

Authors:  G A Rook; R Hernandez-Pando
Journal:  Annu Rev Microbiol       Date:  1996       Impact factor: 15.500

3.  Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.

Authors:  H McShane; R Brookes; S C Gilbert; A V Hill
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine.

Authors:  K Huygen; J Content; O Denis; D L Montgomery; A M Yawman; R R Deck; C M DeWitt; I M Orme; S Baldwin; C D'Souza; A Drowart; E Lozes; P Vandenbussche; J P Van Vooren; M A Liu; J B Ulmer
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

5.  Vaccination against tuberculosis by DNA injection.

Authors:  R E Tascon; M J Colston; S Ragno; E Stavropoulos; D Gregory; D B Lowrie
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent.

Authors:  L G Bekker; A L Moreira; A Bergtold; S Freeman; B Ryffel; G Kaplan
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

7.  NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection.

Authors:  Ana Paula Junqueira-Kipnis; Andre Kipnis; Amanda Jamieson; Mercedes Gonzalez Juarrero; Andreas Diefenbach; David H Raulet; Joanne Turner; Ian M Orme
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

8.  Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein.

Authors:  Yasir A W Skeiky; Mark R Alderson; Pamela J Ovendale; Jeffrey A Guderian; Lise Brandt; Davin C Dillon; Antonio Campos-Neto; Yves Lobet; Wilfried Dalemans; Ian M Orme; Steven G Reed
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

9.  Pulmonary necrosis resulting from DNA vaccination against tuberculosis.

Authors:  Jennifer L Taylor; Oliver C Turner; Randall J Basaraba; John T Belisle; Kris Huygen; Ian M Orme
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

10.  Combined DNA vaccines formulated in DDA enhance protective immunity against tuberculosis.

Authors:  H Cai; X Tian; X D Hu; Y H Zhuang; Y X Zhu
Journal:  DNA Cell Biol       Date:  2004-07       Impact factor: 3.311

View more
  14 in total

1.  Deletion of the Mycobacterium tuberculosis resuscitation-promoting factor Rv1009 gene results in delayed reactivation from chronic tuberculosis.

Authors:  JoAnn M Tufariello; Kaixia Mi; Jiayong Xu; Yukari C Manabe; Anup K Kesavan; Joshua Drumm; Kathryn Tanaka; William R Jacobs; John Chan
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 2.  Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis.

Authors:  Michael J Brennan; Bartholt Clagett; Hillary Fitzgerald; Vicki Chen; Ann Williams; Angelo A Izzo; Lewellys F Barker
Journal:  Vaccine       Date:  2012-03-03       Impact factor: 3.641

3.  Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.

Authors:  Catherine W M Ong; Paul T Elkington; Jon S Friedland
Journal:  Am J Respir Crit Care Med       Date:  2014-07-01       Impact factor: 21.405

4.  A single dose of a DNA vaccine encoding apa coencapsulated with 6,6'-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice.

Authors:  Dyego Carlétti; Denise Morais da Fonseca; Ana Flávia Gembre; Ana Paula Masson; Lívia Weijenborg Campos; Luciana C C Leite; Andréa Rodrigues Pires; Joseli Lannes-Vieira; Célio Lopes Silva; Vânia Luiza Deperon Bonato; Cynthia Horn
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

5.  Metalworking fluid with mycobacteria and endotoxin induces hypersensitivity pneumonitis in mice.

Authors:  Peter S Thorne; Andrea Adamcakova-Dodd; Kevin M Kelly; Marsha E O'neill; Caroline Duchaine
Journal:  Am J Respir Crit Care Med       Date:  2005-12-30       Impact factor: 21.405

Review 6.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

Authors:  Joshua S M Woodworth; Samuel M Behar
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

7.  Vaccine-induced cellular immune responses differ from innate responses in susceptible and resistant strains of mice infected with Coccidioides posadasii.

Authors:  Lisa F Shubitz; Sharon M Dial; Robert Perrill; Rachael Casement; John N Galgiani
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

8.  Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice.

Authors:  Ping Wang; Limei Wang; Wei Zhang; Yinlan Bai; Jian Kang; Yanfei Hao; Tailai Luo; Changhong Shi; Zhikai Xu
Journal:  Hum Vaccin Immunother       Date:  2013-08-27       Impact factor: 3.452

Review 9.  Cell-mediated immune responses in tuberculosis.

Authors:  Andrea M Cooper
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

Review 10.  Heat shock proteins: stimulators of innate and acquired immunity.

Authors:  Camilo A Colaco; Christopher R Bailey; K Barry Walker; James Keeble
Journal:  Biomed Res Int       Date:  2013-05-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.